Logo

CAMP

CAMP4 Therapeutics Corporation

CAMP

CAMP4 Therapeutics Corporation • NASDAQ
$3.80 ▲ 4.97% (+0.18)
Market Cap $80.71 M
52w High $10.80
52w Low $1.30
Dividend Yield 0%
P/E -0.35
Volume 27.46K
Outstanding Shares 21.24M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $795K ▼ $14.446M ▼ $-15.099M ▼ -1.899K% ▼ $-0.55 ▲ $-14.683M ▼
Q2-2025 $1.497M ▲ $14.525M ▲ $-12.587M ▼ -840.815% ▲ $-0.62 ▲ $-12.598M ▲
Q1-2025 $858K ▲ $13.958M ▼ $-12.433M ▲ -1.449K% ▲ $-0.64 ▲ $-12.679M ▲
Q4-2024 $652K ▲ $14.686M ▲ $-13.279M ▲ -2.037K% ▼ $-0.68 ▲ $-13.616M ▼
Q3-2024 $0 $13.516M $-13.484M 0% $-0.69 $-13.098M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $39.052M $51.275M $11.288M $39.987M
Q2-2025 $39.052M ▼ $51.275M ▼ $11.288M ▲ $39.987M ▼
Q1-2025 $49.323M ▼ $62.773M ▼ $11.201M ▼ $51.572M ▼
Q4-2024 $64.039M ▲ $78.307M ▲ $15.163M ▼ $63.144M ▲
Q3-2024 $2.528M $21.364M $180.339M $-158.975M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-15.099M ▼ $-11.217M ▼ $36K ▲ $47.384M ▲ $36.203M ▲ $-11.217M ▼
Q2-2025 $-12.587M ▼ $-10.343M ▲ $0 ▲ $72K ▲ $-10.271M ▲ $-10.343M ▲
Q1-2025 $-12.433M ▲ $-14.286M ▼ $-279K ▼ $-151K ▼ $-14.716M ▼ $-14.565M ▼
Q4-2024 $-13.279M ▲ $-11.288M ▼ $-263K ▼ $73.062M ▲ $61.511M ▲ $-11.551M ▼
Q3-2024 $-13.484M $-9.693M $0 $-386K $-10.079M $-9.693M

Revenue by Products

Product Q1-2023Q2-2023Q3-2023Q4-2023
Application Subscriptions And Other Services
Application Subscriptions And Other Services
 $30.00M ▲$20.00M ▼$20.00M ▲$20.00M ▲
Product
Product
 $50.00M ▲$50.00M ▲$40.00M ▼$30.00M ▼

Five-Year Company Overview

Income Statement

Income Statement CAMP4 looks like a classic early‑stage biotech: almost no meaningful revenue yet and steady losses driven by research and development and other operating costs. Revenue that did exist in prior years has actually drifted down, not up, which suggests past collaboration or grant income rather than a growing commercial business. Profitability metrics have been consistently negative, and per‑share losses have grown as the company has advanced its pipeline and likely increased spending. This is normal for a clinical‑stage platform story, but it means the business today is an R&D engine, not an operating company with recurring sales.

Balance Sheet

Balance Sheet The balance sheet is small and lean, with only modest assets and a heavy reliance on cash. Debt is present relative to the company’s size, and equity has been thin, reflecting accumulated losses over time. That combination signals financial fragility: the business depends on continued access to capital markets or partners to support operations. The IPO in late 2024 likely strengthened the cash position compared with earlier years, but historically the company has not had a large cushion. Overall, this is a typical balance sheet for a young biotech: light on hard assets, dependent on intellectual property and future funding.

Cash Flow

Cash Flow Cash flow has been consistently negative from operations, showing that CAMP4 is burning cash to fund research without offsetting inflows from products. Free cash flow has also been negative, though capital spending needs appear modest, so most of the outflow is tied to people, trials, and platform development rather than equipment. There were brief periods of less negative or near‑break‑even operating cash flow earlier, but the recent trend is clearly toward ongoing cash use. That means the company’s future depends heavily on its ability to raise new capital or secure non‑dilutive funding as clinical programs progress.

Competitive Edge

Competitive Edge CAMP4 occupies a specialized niche in RNA medicines by focusing on regulatory RNAs to turn genes up, rather than just turning them off or replacing them. This gives it a differentiated scientific story in a crowded field that includes well‑funded mRNA and RNA interference players. Its lead programs target rare, high‑need genetic conditions where competition is present but not overwhelming, and in some cases there are no approved disease‑modifying treatments. The main strengths are scientific differentiation and a platform that could scale to multiple diseases. The main risks are its early clinical stage, the presence of larger, better‑funded competitors in adjacent modalities, and the fact that its approach is not yet clinically validated at scale.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of CAMP4. The RNA Actuating Platform is designed to systematically map regulatory RNAs and then use antisense drugs to dial gene expression up, especially in diseases where one working copy of a gene is not enough. Lead assets in urea cycle disorders and SYNGAP1‑related disorders showcase how the platform can be applied to rare genetic conditions with deep unmet need. Early human safety data in one program and advanced preclinical work in another suggest active, ongoing R&D momentum. However, the approach remains scientifically and clinically unproven in later‑stage trials, so technical and development risk is high even though the concept is compelling and differentiated.

Summary

CAMP4 is best understood as a high‑innovation, high‑risk clinical‑stage biotech rather than a traditional operating company. The income statement shows minimal revenue and persistent losses typical of a company still building and testing its pipeline. The balance sheet and cash flow history highlight dependence on external funding and a need for careful capital management as trials advance. Competitively, CAMP4 stands out with a novel focus on regulatory RNA and gene upregulation, targeting serious rare diseases where treatment options are limited. Its platform and pipeline offer meaningful upside potential if the science translates well in humans, but the company remains in the early stages of validation, with significant scientific, clinical, and financing uncertainties ahead.

NEWS

November 14, 2025 · 4:05 PM UTC

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 6, 2025 · 4:05 PM UTC

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

Read more

October 1, 2025 · 8:00 AM UTC

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

Read more

September 10, 2025 · 7:00 AM UTC

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

Read more